Showing results (221-230 of 250) with videos related to
Sort By:
Pageof 25
Cancers|November 26, 2022
Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational StudyNikolaos Spathas, Anna C Goussia, Georgia-Angeliki Koliou, et al.The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.Nature Medicine|October 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trialGeorgina V Long, Charlie Garnett-Benson, Sonia Dolfi, et al.Cancer Immunology, Immunotherapy : CII|June 24, 2021
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, Sofia Lampaki, Georgia-Angeliki Koliou, et al.JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.Breast (Edinburgh, Scotland)|January 4, 2024
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytesFoteinos-Ioannis Dimitrakopoulos, Anna Goussia, Georgia-Angeliki Koliou, et al.Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.Pageof 25